Own the gold standard ✨ in financial data & analytics
fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Subscribe for $2
Overview
Profile

Aptinyx stock price, quote, forecast and news

APTX
US03836N1037
A2JPB1

Price

0.10
Today +/-
+0
Today %
+0 %
P

Aptinyx Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Aptinyx, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Aptinyx from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Aptinyx’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Aptinyx. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Aptinyx’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Aptinyx’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Aptinyx’s growth potential.

Aptinyx Revenue, EBIT and net profit per share

DateAptinyx RevenueAptinyx EBITAptinyx Net Income
2028e142.8 M undefined0 undefined-31.08 M undefined
2027e374.85 M undefined-40.19 M undefined-31.08 M undefined
2026e0 undefined-38.25 M undefined-15.89 M undefined
2025e0 undefined-73.29 M undefined-30.39 M undefined
2024e0 undefined-52.42 M undefined-30.39 M undefined
2023e0 undefined-45.44 M undefined-32.46 M undefined
20220 undefined-62.57 M undefined-64.85 M undefined
20211 M undefined-74.53 M undefined-74.89 M undefined
20201.56 M undefined-50.77 M undefined-50.05 M undefined
20193.67 M undefined-59.61 M undefined-57.41 M undefined
20186.57 M undefined-54.89 M undefined-53.28 M undefined
20174.96 M undefined-32.23 M undefined-32.07 M undefined
20169.79 M undefined-17.72 M undefined-15.48 M undefined

Aptinyx Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)EBIT (M)EBIT MARGIN (%)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
20162017201820192020202120222023e2024e2025e2026e2027e2028e
94631100000374142
--55.5650.00-50.00-66.67--------62.03
-------------
0000000000000
-17-32-54-59-50-74-62-45-52-73-38-400
-188.89-800.00-900.00-1,966.67-5,000.00-7,400.00------10.70-
-15-32-53-57-50-74-64-32-30-30-15-31-31
-113.3365.637.55-12.2848.00-13.51-50.00-6.25--50.00106.67-
32.5432.5433.3433.5648.8767.2267.72000000
-------------
Details

Keystats

ⓘ

Revenue and Growth

The Aptinyx Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Aptinyx is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (M)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Aptinyx provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Aptinyx's financial health and stability.

Assets

Aptinyx's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Aptinyx must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Aptinyx after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Aptinyx's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES (M)TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
2016201720182019202020212022
-15-32-53-57-50-74-64
0000000
0000000
-2-12-4-21-3
-1039998
0000002
0000000
-19-32-47-52-42-63-59
0-100000
0-100000
0000000
0000000
000001410
2410910908500
24109106084289
00-300140
0000000
47558-5142-34-49
-20.09-34.32-47.86-52.13-42.57-63.43-59.68
0000000

Aptinyx stock margins

The Aptinyx margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Aptinyx. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Aptinyx.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Aptinyx's sales revenue. A higher gross margin percentage indicates that the Aptinyx retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Aptinyx's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Aptinyx's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Aptinyx's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Aptinyx. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Aptinyx's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Aptinyx Margin History

Aptinyx Gross marginAptinyx Profit marginAptinyx EBIT marginAptinyx Profit margin
2028e0 %0 %-21.77 %
2027e0 %-10.72 %-8.29 %
2026e0 %0 %0 %
2025e0 %0 %0 %
2024e0 %0 %0 %
2023e0 %0 %0 %
20220 %0 %0 %
20210 %-7,453 %-7,489 %
20200 %-3,254.49 %-3,208.33 %
20190 %-1,624.25 %-1,564.31 %
20180 %-835.46 %-810.96 %
20170 %-649.8 %-646.57 %
20160 %-181 %-158.12 %

Aptinyx Stock Sales Revenue, EBIT, Earnings per Share

The Aptinyx earnings per share therefore indicates how much revenue Aptinyx has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Aptinyx earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Aptinyx's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Aptinyx’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Aptinyx's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Aptinyx Revenue, EBIT and net profit per share

DateAptinyx Sales per ShareAptinyx EBIT per shareAptinyx Earnings per Share
2028e2.11 undefined0 undefined-0.46 undefined
2027e5.54 undefined0 undefined-0.46 undefined
2026e0 undefined0 undefined-0.23 undefined
2025e0 undefined0 undefined-0.45 undefined
2024e0 undefined0 undefined-0.45 undefined
2023e0 undefined0 undefined-0.48 undefined
20220 undefined-0.92 undefined-0.96 undefined
20210.01 undefined-1.11 undefined-1.11 undefined
20200.03 undefined-1.04 undefined-1.02 undefined
20190.11 undefined-1.78 undefined-1.71 undefined
20180.2 undefined-1.65 undefined-1.6 undefined
20170.15 undefined-0.99 undefined-0.99 undefined
20160.3 undefined-0.54 undefined-0.48 undefined

Aptinyx business model

Aptinyx Inc is a biopharmaceutical company specializing in the development of therapies for the treatment of neurological diseases. The company was founded in 2015 in Evanston, Illinois, USA, and has since achieved an impressive track record in researching and developing innovative therapies. The history of Aptinyx Inc begins with a group of experienced scientists and researchers who came together to push the boundaries of neuroscience research and discover new treatment options for people with brain disorders. The company is based on the belief that the human brain is a fascinating and complex entity that still holds many secrets. The company is committed to improving human well-being through innovative neurotherapeutic products and services. Aptinyx Inc's business model focuses on the research, development, and commercialization of novel therapeutic treatments for neurological diseases. The company closely collaborates with leading academic institutions and facilities to leverage the best research findings and methods. The company has a strong scientific foundation led by an experienced team of researchers and developers working on innovative biomarker and therapy strategies. Aptinyx Inc has focused on the development of neuromodulators and neuroprotectants to treat neurological diseases, including pain disorders, peripheral neuropathies, neuropathic pain, Parkinson's disease, post-traumatic stress disorder (PTSD), and other central nervous system disorders. Aptinyx Inc's products are based on a comprehensive understanding of the fundamentals of the nervous system and how it functions. The company offers a variety of products and services, including novel therapeutics for the treatment of pain, neuropathy, and other neurological diseases. These products are based on the utilization of Aptinyx's proprietary technologies to selectively modulate specific cell types and signaling pathways in the nervous system. The products and services of Aptinyx Inc have been regulated by leading health authorities in the US and Europe. Aptinyx Inc has two main divisions of products: the first focus is on the development of neuromodulators that specifically alleviate pain and modulate the brain. The second focus is on the development of neuroprotectants that help protect neurons and reduce inflammation in the nervous system. These two divisions are closely interconnected as they are based on a common platform grounded in the exploration of novel biomarkers and therapeutic targets. The products of Aptinyx Inc are designed for both pain relief and improvement of neural functions. Additionally, these products aim to enhance patient experience and quality of life. The company consistently collaborates with potential partners and experts to develop products tailored to the needs of patients and healthcare providers. Overall, Aptinyx Inc has revolutionized the world of neuroscience by exploring and developing innovative solutions for neurological diseases. The company has achieved an impressive track record by utilizing its scientific expertise and groundbreaking technologies to set new trends in neuroscience research and therapeutics. In summary, Aptinyx Inc has developed a unique approach to the development of neuromodulators and neuroprotectants based on a deep understanding of the structure and function of the nervous system. The products and services of the company have the potential to play a significant role in improving the quality of life for patients with neurological diseases. Aptinyx is one of the most popular companies on Eulerpool.com.

Aptinyx SWOT Analysis

Strengths

  • Strong scientific expertise in the field of NMDA receptor modulation.
  • Patented technology and intellectual property portfolio related to NMDA receptor modulators.
  • Promising pipeline of drug candidates targeting various neurological and psychiatric disorders.
  • Strategic partnerships and collaborations with leading pharmaceutical companies.
  • Experienced and talented research and development team.

Weaknesses

  • Relatively small size and limited resources compared to larger pharmaceutical companies.
  • Dependency on successful clinical trials and regulatory approvals for drug candidates.
  • High competition in the neuroscience therapeutics market.
  • Limited commercialization experience and marketing capabilities.

Opportunities

  • Growing demand for innovative treatments in neurology and psychiatry.
  • Potential for market expansion through strategic partnerships and licensing agreements.
  • Increasing awareness and understanding of NMDA receptor modulation in the medical community.
  • Emerging markets with untapped potential for neurological and psychiatric therapies.
  • Government support and funding for research and development in the healthcare sector.

Threats

  • Stringent regulatory requirements and approval processes for pharmaceutical products.
  • Potential safety and efficacy concerns associated with NMDA receptor modulation.
  • Intense competition from established pharmaceutical companies with greater resources.
  • Economic fluctuations and changes in healthcare policies affecting market dynamics.
  • Failure or setbacks in clinical trials leading to delays or termination of drug development programs.

Aptinyx historical P/E ratio, EBIT, and P/S ratio.

Aptinyx shares outstanding

The number of shares was Aptinyx in 2023 — This indicates how many shares 67.72 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Aptinyx earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Aptinyx's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Aptinyx’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Aptinyx's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Aptinyx dividend history and estimates

In 2023, Aptinyx paid a dividend amounting to 0 USD. Dividend means that Aptinyx distributes a portion of its profits to its owners.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Dividend
Dividend (Estimate)
Details

Dividend

ⓘ

Dividend Overview

The dividend per year chart for Aptinyx provides a comprehensive view of the annual dividends distributed to shareholders. Analyze the trend to understand the consistency and growth in dividend payouts over the years.

Interpretation and Use

A consistent or increasing trend in dividends can indicate the company's profitability and financial health. Investors can use this data to identify Aptinyx’s potential for long-term investment and income generation through dividends.

Investment Strategy

Incorporate the dividend data in evaluating Aptinyx's overall performance. A thorough analysis, considering other financial aspects, will help in making informed investment decisions for optimal capital growth and income generation.

Aptinyx Dividend History

DateAptinyx Dividend
Aptinyx does not pay out any dividends.
Unfortunately, there are currently no price targets and forecasts available for Aptinyx.

Aptinyx latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
12/31/2022-0.2 -0.18  (8.35 %)2022 Q4
9/30/2022-0.25 -0.23  (6.43 %)2022 Q3
6/30/2022-0.29 -0.26  (9.25 %)2022 Q2
3/31/2022-0.31 -0.29  (6.39 %)2022 Q1
12/31/2021-0.35 -0.29  (17.73 %)2021 Q4
9/30/2021-0.32 -0.31  (3 %)2021 Q3
6/30/2021-0.26 -0.29  (-13.73 %)2021 Q2
3/31/2021-0.22 -0.22  (0.95 %)2021 Q1
12/31/2020-0.25 -0.2  (19.97 %)2020 Q4
9/30/2020-0.3 -0.24  (20.24 %)2020 Q3
1
2

Eulerpool ESG Scorecard© for the Aptinyx stock

Eulerpool World ESG Rating (EESG©)

34/ 100

🌱 Environment

38

👫 Social

30

🏛️ Governance

35

Environment

Scope 1 - Direct Emissions
—
Scope 2 - Indirect emissions from purchased energy
—
Scope 3 - Indirect emissions within the value chain
—
Total CO₂ emissions
—
CO₂ reduction strategy
✅
Coal energy
❌
Nuclear power
❌
Animal experiments
✅
Fur & Leather
—
Pesticides
—
Palm Oil
—
Tobacco
❌
Genetically modified organisms
❌
Climate concept
—
Sustainable forestry
—
Recycling regulations
❌
Environmentally friendly packaging
❌
Hazardous substances
❌
Fuel consumption and efficiency
❌
Water consumption and efficiency
❌

Social

Percentage of female employees—
Percentage of women in management—
Percentage of Asian employees—
Share of Asian management—
Percentage of Hispanic/Latino employees—
Hispano/Latino Management share—
Percentage of Black employees—
Black Management Share—
Percentage of white employees—
White Management Share—
Adult content❌
Alcohol❌
Weapons—
Firearms
❌
Gambling❌
Military contracts❌
Human rights concept❌
Privacy concept—
Occupational health and safety❌
Catholic✅

Governance (Corporate Governance)

Environmental reporting❌
Stakeholder Engagement❌
Call Back Policies❌
Antitrust law❌

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Aptinyx list of shareholders

%
Name
Stocks
Change
Date
9.80 % Kryzanowski (John A)6,637,800746,99812/31/2022
2.00 % Riedel (Norbert G)1,355,87304/24/2023
0.62 % Khanna (Ashish)421,84004/24/2023
0.34 % Hombach (Robert J)229,10004/24/2023
0.33 % Acadian Asset Management LLC224,265-155,0616/30/2023
0.18 % Gosebruch (Henry O)125,00004/24/2023
0.16 % Northwestern University109,28006/30/2023
0.15 % Kidd (Andrew)101,04304/24/2023
0.03 % Miller (Joan W)17,70004/24/2023
0.00 % Blackstone Alternative Investment Advisors LLC3,100-1,9003/31/2023
1
2
3
4
5
...
10

Most common questions regarding Aptinyx

What values and corporate philosophy does Aptinyx represent?

Aptinyx Inc represents a corporate philosophy centered around innovation, patient-centricity, and scientific excellence. As a leading biopharmaceutical company, Aptinyx is dedicated to developing novel therapies that address significant unmet medical needs in the field of neuroscience. The company's core values include a commitment to groundbreaking research, cutting-edge technology, and collaboration with academic and industry partners. Aptinyx aims to improve the lives of patients and their families by advancing transformative medicines. Through their steadfast dedication and emphasis on scientific rigor, Aptinyx Inc is at the forefront of discovering innovative solutions for neurological disorders.

In which countries and regions is Aptinyx primarily present?

Aptinyx Inc is primarily present in the United States.

What significant milestones has the company Aptinyx achieved?

Some significant milestones achieved by Aptinyx Inc include the successful completion of Phase 2 clinical trials for their lead drug candidate, NYX-2925, in the treatment of chronic pain and post-traumatic stress disorder (PTSD). Additionally, Aptinyx Inc has presented positive data demonstrating the drug's potential benefits in improving cognitive function and reducing symptoms associated with central nervous system disorders. The company has also collaborated with prominent organizations and received grants, reflecting its recognition in the field. With these achievements, Aptinyx Inc is positioned as a promising player in the development of innovative therapies for neurological and psychiatric disorders.

What is the history and background of the company Aptinyx?

Aptinyx Inc. is a biopharmaceutical company specializing in the discovery and development of novel therapies to treat brain and nervous system disorders. Founded in 2015, Aptinyx is headquartered in Evanston, Illinois. The company focuses on the development of selective N-methyl-D-aspartate (NMDA) receptor modulators, which have the potential to address a range of neurological and psychiatric conditions. Aptinyx's pipeline includes drug candidates targeting conditions such as chronic pain, Parkinson's disease, and post-traumatic stress disorder (PTSD). With a commitment to improving patients' lives, Aptinyx is dedicated to advancing its innovative therapies through rigorous clinical trials and regulatory processes.

Who are the main competitors of Aptinyx in the market?

The main competitors of Aptinyx Inc in the market include other pharmaceutical companies operating in the field of neuroscience and developing novel therapies for central nervous system disorders. These competitors may include companies such as Biogen Inc., Celgene Corporation, and Johnson & Johnson.

In which industries is Aptinyx primarily active?

Aptinyx Inc is primarily active in the biotechnology and pharmaceutical industries.

What is the business model of Aptinyx?

Aptinyx Inc's business model revolves around developing and commercializing novel therapies for treating neurological disorders. The company primarily focuses on targeting the brain's N-methyl-D-aspartate (NMDA) receptor pathway to address conditions such as post-traumatic stress disorder (PTSD), neuropathic pain, and cognitive dysfunction. By utilizing a proprietary platform, Aptinyx aims to bring innovative medicines to market that can provide significant benefits to patients in need. Through strategic collaborations and advancements in neuroscience research, Aptinyx strives to create value for its shareholders while improving patient outcomes in the field of neurology.

What is the P/E ratio of Aptinyx 2024?

The Aptinyx P/E ratio is -0.21.

What is the P/S ratio of Aptinyx 2024?

The Aptinyx P/S ratio is 0.

What is the AlleAktien quality score of Aptinyx?

The AlleAktien quality score for Aptinyx is 1/10.

What is the revenue of Aptinyx 2024?

The revenue cannot currently be calculated for Aptinyx.

How high is the profit of Aptinyx 2024?

The expected Aptinyx profit is -30.39 M USD.

What is the business model of Aptinyx

Aptinyx Inc is a biopharmaceutical company specializing in the development of novel therapeutics for the central nervous system. Founded in 2015 in Evanston, Illinois, Aptinyx focuses on discovering revolutionary therapies with a focus on neuromodulatory agents that can modify the brain's signaling systems. The business model of Aptinyx is based on identifying new target molecules, developing new drugs, and conducting clinical trials to assess the safety and efficacy of the drugs. The company also has partnerships with other pharmaceutical companies that support the discovery and development of new therapeutics. Aptinyx is dedicated to developing effective therapies for neurological disorders such as chronic pain, neuropathic pain, post-traumatic stress disorder (PTSD), and other conditions. The company operates in various areas and has multiple product candidates at different stages of development, from exploration to clinical development. One of these product candidates is NYX-784, a modulatory agent primarily used for the treatment of neuropathies and chronic pain. Aptinyx initiated clinical trials for NYX-784 in 2020. Another product candidate is NYX-458, a medication for the treatment of central sensitization conditions such as fibromyalgia or migraines. Clinical trials for NYX-458 are also being planned. The company also offers services in various areas, including the identification of novel targets and molecules, drug development, and the conduct of clinical trials. Aptinyx's services are aimed at both other pharmaceutical companies and academic institutes. Aptinyx also has partnerships with other companies in the pharmaceutical and biotech industry. In 2019, Aptinyx and Allergan entered into an agreement for the development and commercialization of NYX-2925, a medication for the treatment of depression. The agreement also includes Allergan acquiring a majority stake in Aptinyx valued at approximately $125 million. Overall, Aptinyx's business model has the potential to radically improve the treatment of neurological disorders. With a strong pipeline of product candidates, significant partnerships, and a dedicated team of researchers and developers, the company is on track to make a real difference in the field of neuromodulatory therapies.

What is the Aptinyx dividend?

Aptinyx pays a dividend of 0 USD distributed over payouts per year.

How often does Aptinyx pay dividends?

The dividend cannot currently be calculated for Aptinyx or the company does not pay out a dividend.

What is the Aptinyx ISIN?

The ISIN of Aptinyx is US03836N1037.

What is the Aptinyx WKN?

The WKN of Aptinyx is A2JPB1.

What is the Aptinyx ticker?

The ticker of Aptinyx is APTX.

How much dividend does Aptinyx pay?

Over the past 12 months, Aptinyx paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Aptinyx is expected to pay a dividend of 0 USD.

What is the dividend yield of Aptinyx?

The current dividend yield of Aptinyx is .

When does Aptinyx pay dividends?

Aptinyx pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Aptinyx?

Aptinyx paid dividends every year for the past 0 years.

What is the dividend of Aptinyx?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Aptinyx located?

Aptinyx is assigned to the 'Health' sector.

Wann musste ich die Aktien von Aptinyx kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Aptinyx from 12/29/2023 amounting to 0.099 USD, you needed to have the stock in your portfolio before the ex-date on 1/2/2024.

When did Aptinyx pay the last dividend?

The last dividend was paid out on 12/29/2023.

What was the dividend of Aptinyx in the year 2023?

In the year 2023, Aptinyx distributed 0 USD as dividends.

In which currency does Aptinyx pay out the dividend?

The dividends of Aptinyx are distributed in USD.

All fundamentals about Aptinyx

Our stock analysis for Aptinyx Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Aptinyx Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.